Relation of Hormone-Replacement Therapy to Measures of Plasma Fibrinolytic Activity

Circulation

Volumn 93, Issue 11, 1996, Pages 1970-1975

  Shahar, Eyal ^a   Folsom, Aaron R ^a   Salomaa, Veikko V ^b   Stinson, Valarie L ^c   McGovern, Paul G ^a   Shimakawa, Tomoko ^d   Chambless, Lloyd E ^e   Wu, Kenneth K ^c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^d NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Atherosclerosis; Fibrinolysis; Hormones

Indexed keywords

DIMER; ESTROGEN; GESTAGEN; HORMONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; ECHOGRAPHY; ENZYME IMMUNOASSAY; FEMALE; FIBRINOLYSIS; HORMONE SUBSTITUTION; HUMAN; INTIMA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MENOPAUSE; PRIORITY JOURNAL;

ALCOHOL DRINKING; ARTERIOSCLEROSIS; BLOOD GLUCOSE; COHORT STUDIES; CORONARY DISEASE; ESTROGEN REPLACEMENT THERAPY; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOLYSIS; HUMANS; INSULIN; LIPIDS; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; RISK FACTORS; SMOKING; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0029889934     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.93.11.1970     Document Type: Article

References (48)

1. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med. 1991;20:47-63.
2. Belchetz PE. Hormonal treatment of postmenopausal women. N Engl J Med. 1994;330:1062-1071.
3. Nabulsi AA, Folsom AR, White A, Patsch W, Heiss G, Wu KK, Szklo M. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med. 1993;328:1069-1075.
4. Manolio TA, Furberg CD, Shemanski L, Psaty BM, O'Leary DH, Tracy RP, Bush TL. Associations of postmenopausal estrogen use with cardiovascular disease and its risk factors in older women. Circulation. 1993;88(pt 1):2163-2171.
5. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet. 1993;342:1076-1079.
6. Salomaa V, Stinson V, Kark JD, Folsom, AR, Davis CE, Wu KK. Association of fibrinolytic parameters with early atherosclerosis: the ARIC Study. Circulation. 1995;91:284-290.
7. Olofsson BO, Dahlen G, Nilsson TK. Evidence for increased levels of plasminogen inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease. Eur Heart J. 1989;10:77-82.
8. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet. 1993;341:1165-1168.
9. Hamsten A, Walldius G, Szamosi A, Blombäck M, Faire U, Dahlen G, Landou C, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987;2:3-9.
10. Cortellaro M, Cofrancesco E, Boschetti C, Mussoni L, Donati MB, Cardillo M, Catalano L, Gabrielli L, Lombardi B, Specchia G, Tavazzi L, Tremoli E, Pozzoli E, Turri M, for the PLAT Group. Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients: a case-control study. Arterioscler Thromb. 1993;13:1412-1417.
11. Ridker PM, Hennekens CH, Stampfer MJ, Manson JE, Vaughan DE. Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet. 1994;343:940-943.
12. Jansson JH, Olofsson BO, Nilsson TK. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease: a 7-year follow-up. Circulation. 1993;88(pt 1):2030-2034.
13. The ARIC Investigators. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. Am J Epidemiol. 1989;129: 687-702.
14. Riley WA, Barnes RW, Bond MG, Evans G, Chambless LE, Heiss G, for the ARIC Study Group. High resolution B-mode ultrasound reading methods in the Atherosclerosis Risk in Communities (ARIC) cohort. J Neuroimaging. 1991;1:168-172.
15. Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R. Intimal plus medial thickness of arterial wall: a direct measurement with ultrasound imaging. Circulation. 1986;74:1399-1406.
16. Heiss G, Sharrett AR, Barnes R, Chambless LE, Szklo M, Alzola C, and the ARIC Investigators. Carotid atherosclerosis measured by B-mode ultrasound in populations: associations with cardiovascular risk factors in the ARIC Study. Am J Epidemiol. 1991;134:250-256.
17. Papp AC, Hatzakis H, Bracey A, Wu KK. ARIC Hemostasis Study, I: development of a blood collection and processing system suitable for multicenter hemostatic studies. Thromb Haemost. 1989;61: 15-19.
18. Wu KK, Papp AC, Patsch W, Rock R, Eckfeldt J, Sharrett R. ARIC Hemostasis Study, II: organizational plan and feasibility study. Thromb Haemost. 1990;64:521-525.
19. Atherosclerosis Risk in Communities Manual 9: Hemostasis Determinations. Chapel Hill, NC: National Heart, Lung, and Blood Institute of the National Institute of Health, Collaborative Studies Coordinating Center, University of North Carolina; April 28, 1987.
20. Nägele U, Hägele EO, Sauer G, Wiedemann E, Lehmann P, Walefeld AW. Reagent for the enzymatic determination of serum total triglycerides with improved lipolytic efficiency. J Clin Chem Clin Biochem. 1984;22:165-174.
21. Siedel J, Hagele EO, Ziegenhorn J, Wahlefeld AW. Reagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency. Clin Chem. 1983;29:1075-1080.
22. SAS/STAT User's Guide: Version 6. 4th ed. Cary, NC: SAS Institute; 1990.
23. Andreotti F, deBart ACW, Regan T, Maseri A, Kluft C. Factors affecting the relation between plasminogen activator inhibitor (PAI) activity and PAI-1 antigen levels in normals and in patients with arterial disease. Fibrinolysis. 1990;4(suppl 2):134-135.
24. Hamsten A, Winman B, deFaire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of acute myocardial infarction. N Engl J Med. 1985;313: 1557-1563.
25. Juhan-Vague I, Rijken DC, de Cock F, Mendez C, Collen D. Extrinsic plasminogen activator levels in clinical plasma samples. Proc Fibrinol. 1983;6:65-69.
26. Meilahn EN, Kuller LH, Matthews KA, Kiss JE. Hemostatic factors according to menopausal status and use of hormone replacement therapy. Ann Epidemiol. 1992;2:445-455.
27. Scarabin PY, Plu-Bureau G, Bara L, Bonithon-Kopp C, Guize L, Samama MM. Haemostatic variables and menopausal status: influence of hormone replacement therapy. Thromb Haemost. 1993; 70:584-587.
28. Meilahn EN, Cauley JA, Tracy RP, Macy EM, Gutai JP, Kuller LH. Variation in plasma fibrinogen and PAI-1 by sex hormones and adiposity among older women. Circulation. 1993;87(suppl I):I-15. Abstract.
29. Gebara OCE, Mittleman MA, Sutherland P, Lipinska I, Matheney T, Xu P, Welty FK, Wilson PWF, Levy D, Muller JE, Tofler GH. Association between increased estrogen status and increased fibrinolytic potential in the Framingham offspring study. Circulation. 1995;91:1952-1958.
30. Notelovitz M, Kitchens CS, Ware MD. Coagulation and fibrinolysis in estrogen-treated surgically menopausal women. Obstet Gynecol. 1984;63:621-625.
31. Sporrong T, Mattsson LA, Samsioe G, Stigendal L, Hellgren M. Haemostatic changes during continuous oestradiol-progestogen treatment of postmenopausal women. Br J Obstet Gynaecol. 1990; 97:939-944.
32. Boschetti C, Cortellaro M, Nencioni T, Bertolli V, Della Volpe A, Zanussi C. Short- and long-term effects of hormone replacement therapy (transdermal estradiol vs oral conjugated equine estrogens, combined with medroxyprogesterone acetate) on blood coagulation factors in postmenopausal women. Thromb Res. 1991;62:1-8.
33. Vague P, Juhan-Vague I, Aillaud MR, Badier C, Viard R, Alessi MC, Collen D. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. Metabolism. 1986;35: 250-253.
34. Vague P, Juhan-Vague I, Chabert V, Alessi MC, Atlan C. Fat distribution and plasminogen activator inhibitor activity in nondiabetic obese women. Metabolism. 1989;38:913-915.
35. Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor 1 levels: a possible link between insulin resistance and atherothrombosis. Diabetologia. 1991;34:457-462.
36. Folsom AR, Qamhieh HT, Wing RR, Jeffery RW, Stinson VL, Kuller LH, Wu KK. Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII, and other hemostatic factors in moderately overweight adults. Arterioscler Thromb. 1993;13:162-169.
37. Juhan-Vague I, Vague P. Interrelations between carbohydrates, lipids, and the hemostatic system in relation to the risk of thrombotic and cardiovascular disease. Am J Obstet Gynecol. 1990; 163:313-315.
38. Williams B. Insulin resistance: the shape of things to come. Lancet. 1994;1:521-524.
39. Schneider DJ, Sobel BE. Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type I: implications for vascular disease in hyperinsulinemic states. Proc Natl Acad Sci U S A. 1991;88:9959-9963.
40. Nordt TK, Schneider DJ, Sobel BE. Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin: a potential risk factor for vascular disease. Circulation. 1994;89: 321-330.
41. Barrett-Connor E, Laakso M. Ischemic heart disease risk in postmenopausal women: effects of estrogen use on glucose and insulin levels. Arteriosclerosis. 1990;10:531-534.
42. Heinrich J, Dirkes-Kersting A, Schulte H, Assmann G. Effects of age, menopause and human growth hormone on variables of fibrinolysis. Fibrinolysis. 1992;6(suppl 3):33-35.
43. Lindoff C, Petersson F, Lecander I, Martinsson G, Åstedt B. Passage of the menopause is followed by haemostatic changes. Maturitas. 1993;17:17-22.
44. Winkler UH. Menopause, hormone replacement therapy and cardiovascular disease: a review of haemostaseological findings. Fibrinolysis. 1992;6(suppl 3):5-10.
45. Hjortland MC, McNamara PM, Kannel WB. Some atherogenic concomitants of menopause: the Framingham Study. Am J Epidemiol. 1976;103:304-311.
46. Matthews KA, Meilahn E, Kuller LH, Kelsey SF, Caggiula AW, Wing RR. Menopause and risk factors for coronary heart disease. N Engl J Med. 1989;321:641-646.
47. Bonithon-Kopp C, Scarabin PY, Darne B, Malmejac A, Guize L. Menopause-related changes in lipoproteins and some other cardiovascular risk factors. Int J Epidemiol. 1990;19:42-48.
48. Ridker PM, Vaughan DE, Stampfer MJ, Sacks FM, Hennekens CH. A cross-sectional study of endogenous tissue plasminogen activator, total cholesterol, HDL cholesterol, and apolipoprotein A-I, A-II, and B-100. Arterioscler Thromb. 1993;13:1587-1592.